HELX Franklin Genomic Advancements ETF
ETF on NYSE (US) · Actively managed · Listing
Most notable sale · Medpace Holdings, Inc.
Medpace Holdings, Inc. cut by 15%
Shares went from 1,327 to 1,133 ($637K → $600K). Now 2.2% of the portfolio. Estimated trade $103K.
Most notable buy · Guardant Health, Inc.
Guardant Health, Inc. raised by 8%
Shares went from 15,718 to 16,927 ($1.45M → $2.54M). Now 9.2% of the portfolio. Estimated trade $181K.
Largest holding: Guardant Health, Inc., raised 8%, 16,927 shares ($2.54M).
| Current positions Top 10 | % of book |
|---|---|
| Guardant Health, Inc. GH $2.54M · +8% sh | 9.2% |
| Natera, Inc. NTRA $2.08M · +8% sh | 7.6% |
| Krystal Biotech, Inc. KRYS $1.77M · +8% sh | 6.4% |
| Ligand Pharmaceuticals Incorporated LGND $1.29M · +8% sh | 4.7% |
| Adaptive Biotechnologies Corporation ADPT $1.11M · +8% sh | 4.0% |
| United Therapeutics Corporation UTHR $980K · +8% sh | 3.6% |
| BridgeBio Pharma, Inc. BBIO $978K · +8% sh | 3.5% |
| Eli Lilly and Company LLY $825K · +16% sh | 3.0% |
| Twist Bioscience Corporation TWST $796K · +8% sh | 2.9% |
| Vertex Pharmaceuticals Incorporated VRTX $767K · +8% sh | 2.8% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against Mar 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 91.3% |
| Financial Services | 4.7% |
| Basic Materials | 2.3% |
| Technology | 1.0% |
| Unclassified | 0.8% |
| Industries | % of holdings value |
|---|---|
| Biotechnology | 52.6% |
| Diagnostics & Research | 24.4% |
| Drug Manufacturers - General | 6.0% |
| Asset Management | 4.7% |
| Health Information Services | 3.4% |
| Drug Manufacturers - Specialty & Generic | 2.3% |
| Agricultural Inputs | 2.3% |
| Other (3) | 3.5% |
| Unclassified | 0.8% |
| Initiations 4 | Value |
|---|---|
| Kiniksa Pharmaceuticals International, plc KNSA 0.3% of portfolio | $94.6K |
| Liquidia Corporation LQDA 0.3% of portfolio | $69.4K |
| TG Therapeutics, Inc. TGTX 0.2% of portfolio | $68.8K |
| First Tracks Biotherapeutics, Inc. TRAX 0.2% of portfolio | $55.8K |
| Increases 51 | Change |
|---|---|
| Guardant Health, Inc. GH $1.45M → $2.54M | +8% |
| AnaptysBio, Inc. ANAB $113K → $290K | 2.1x |
| Travere Therapeutics, Inc. TVTX $301K → $724K | +26% |
| Natera, Inc. NTRA $1.43M → $2.08M | +8% |
| Krystal Biotech, Inc. KRYS $1.14M → $1.77M | +8% |
| Eli Lilly and Company LLY $545K → $825K | +16% |
| Ligand Pharmaceuticals Incorporated LGND $757K → $1.29M | +8% |
| Axsome Therapeutics, Inc. AXSM $95.7K → $229K | +65% |
| Adaptive Biotechnologies Corporation ADPT $670K → $1.11M | +8% |
| United Therapeutics Corporation UTHR $996K → $980K | +8% |
| BridgeBio Pharma, Inc. BBIO $905K → $978K | +8% |
| Cadence Design Systems, Inc. CDNS $151K → $272K | +33% |
| Reductions 6 | Change |
|---|---|
| Medpace Holdings, Inc. MEDP $637K → $600K | −15% |
| GeneDx Holdings Corp. WGS $90.5K → $39.5K | −59% |
| Danaher Corporation DHR $199K → $160K | −20% |
| Tarsus Pharmaceuticals, Inc. TARS $104K → $71.5K | −24% |
| Recursion Pharmaceuticals, Inc. RXRX $31.9K → $20.2K | −47% |
| BioNTech SE BNTX $386K → $387K | −4% |
| Terminations 2 | Change |
|---|---|
| TransMedics Group, Inc. TMDX was $47.9K | −100% |
| Caris Life Sciences, Inc. CAI was $9.96K | −100% |
The other 39 increases
Ionis Pharmaceuticals, Inc. (+13%), Neurocrine Biosciences, Inc. (+14%), Veracyte, Inc. (+15%), Twist Bioscience Corporation (+8%), Vertex Pharmaceuticals Incorporated (+8%), AstraZeneca (+8%), Insmed Incorporated (+8%), Corteva, Inc. (+8%), SAMSUNG BIOLOGICS (+8%), Tempus AI, Inc. (+8%), Alnylam Pharmaceuticals, Inc. (+8%), Regeneron Pharmaceuticals, Inc. (+8%), argenx SE (+8%), PTC Therapeutics, Inc. (+8%), Stoke Therapeutics, Inc. (+8%), Charles River Laboratories International, Inc. (+8%), GRAIL, Inc. (+8%), CRISPR Therapeutics AG (+8%), Repligen Corporation (+8%), Beam Therapeutics Inc. (+8%) and 19 more
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Jun 30, 2026 (Form N-PORT) vs the portfolio of Mar 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Aug 3, 2026.
Capital appreciation.
Principal investment strategies
Under normal market conditions, the Fund invests at least 80% of its net assets in equity securities of companies that are relevant to the Fund's investment theme of genomic advancements. The Fund invests predominantly in common stock. Companies relevant to the Fund's investment theme of genomic advancements are those that the investment manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and diagnostics, pharmaceuticals and agricultural applications of genomics, and related equipment, techniques and processes. In pursuing the Fund's investment theme, the investment manager may invest in companies in any economic sector or of any market capitalization and may invest in companies both inside and outside of the United States, including those in developing or emerging markets. Although the Fund may invest across economic sectors, the Fund concentrates its investments in health care related industries. The Fund is a "non-diversified" fund, which means it generally invests a greater proportion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund. In selecting companies that the investment manager believes are relevant to the Fund's investment theme of genomic advancements, the investment manager seeks to identify, using its own fundamental, "bottom-up" research and analysis, companies positioned to capitalize on disruptive innovation in or that are enabling the further development of the genomic advancements theme in the markets in which they operate. The investment manager's internal research and analysis leverages insights from diverse sources, including external research, to develop and refine its investment theme and identify and take advantage of trends that have ramifications for individual companies or entire industries. The investment manager also evaluates market segments, products, services and business models www.franklintempleton.com Summary Prospectus 3 FRANKLIN GENOMIC ADVANCEMENTS ETF SUMMARY PROSPECTUS positioned to benefit significantly from advancements in genomics relative to broad securities markets, and seeks to identify the primary beneficiaries of new trends or developments in genomics to select investments for the Fund. The investment manager may seek to sell a security if: (i) the security reaches its valuation target; (ii) the security reaches its position size limit in the Fund's portfolio; (iii) the security's fundamentals deteriorate; (iv) there are adverse policy changes that could affect the security's outlook; or (v) better investment opportunities become available.
Management and Contact
- Adviser
- Franklin Advisers, Inc.
- Portfolio managers
-
Matthew J. Moberg, CPA Senior Vice President of Advisers and portfolio manager of the Fund since inception (2020).
- [email protected]
Track Record as of Dec 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | 5 Years | Since Inception | |
|---|---|---|---|
| Russell 3000® Index (index reflects no deduction for fees, expenses or taxes) | 17.15% | 13.15% | 15.36% |
Holdings as of Jun 30, 2026
The full portfolio as of the quarter end Jun 30, 2026, from the fund's report to the SEC (Form N-PORT, filed Aug 27, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of Mar 31, 2026.
63 lines, 60 linked, weights sum to 98.73% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| GUARDANT HEALTH INC | GH US40131M1099 | Equity | 16,927 | +1,209 | 9.09% | $ 2.54M |
| NATERA INC | NTRA US6323071042 | Equity | 7,679 | +548 | 7.46% | $ 2.084M |
| KRYSTAL BIOTECH INC | KRYS US5011471027 | Equity | 4,757 | +339 | 6.33% | $ 1.768M |
| LIGAND PHARMACEUTICALS INC | LGND US53220K5048 | Equity | 4,085 | +291 | 4.62% | $ 1.291M |
| ADAPTIVE BIOTECHNOLOGIES CORP | ADPT US00650F1093 | Equity | 51,956 | +3,711 | 3.99% | $ 1.114M |
| UNITED THERAPEUTICS CORP | UTHR US91307C1027 | Equity | 1,809 | +129 | 3.51% | $ 980.17K |
| BRIDGEBIO PHARMA INC | BBIO US10806X1028 | Equity | 13,129 | +937 | 3.50% | $ 977.848K |
| ELI LILLY & COMPANY | LLY US5324571083 | Equity | 688 | +95 | 2.95% | $ 825.208K |
| TWIST BIOSCIENCE CORP | TWST US90184D1000 | Equity | 7,736 | +552 | 2.85% | $ 795.88K |
| VERTEX PHARMACEUTICALS INC | VRTX US92532F1003 | Equity | 1,545 | +110 | 2.75% | $ 767.448K |
| ASTRAZENECA PLC | AZN GB0009895292 | Equity | 3,979 | +284 | 2.70% | $ 754.498K |
| TRAVERE THERAPEUTICS INC | TVTX US89422G1076 | Equity | 12,753 | +2,624 | 2.59% | $ 724.498K |
| INSMED INC | INSM US4576693075 | Equity | 6,388 | +456 | 2.44% | $ 681.089K |
| SAMSUNG BIOLOGICS CO LTD | 207940 KR7207940008 | Equity | 702 | +50 | 2.26% | $ 630.273K |
| CORTEVA INC | CTVA US22052L1044 | Equity | 7,435 | +531 | 2.25% | $ 629.67K |
| MEDPACE HOLDINGS INC | MEDP US58506Q1094 | Equity | 1,133 | −194 | 2.15% | $ 600.025K |
| ALNYLAM PHARMACEUTICALS INC | ALNY US02043Q1076 | Equity | 1,816 | +129 | 1.96% | $ 546.67K |
| TEMPUS AI INC | TEM US88023B1035 | Equity | 9,397 | +671 | 1.95% | $ 544.368K |
| IONIS PHARMACEUTICALS INC | IONS US4622221004 | Equity | 6,739 | +782 | 1.91% | $ 534.335K |
| NEUROCRINE BIOSCIENCES INC | NBIX US64125C1099 | Equity | 3,058 | +365 | 1.84% | $ 515.38K |
| REGENERON PHARMACEUTICALS INC | REGN US75886F1075 | Equity | 805 | +57 | 1.80% | $ 501.95K |
| VERACYTE INC | VCYT US92337F1075 | Equity | 7,819 | +1,031 | 1.64% | $ 459.21K |
| ARGENX SE | ARGX NL0010832176 | Equity | 494 | +35 | 1.64% | $ 458.271K |
| PTC THERAPEUTICS INC | PTCT US69366J2006 | Equity | 5,009 | +357 | 1.46% | $ 408.584K |
| BIONTECH SE | BNTX US09075V1026 | Equity | 4,156 | −184 | 1.38% | $ 386.716K |
| STOKE THERAPEUTICS INC | STOK US86150R1077 | Equity | 11,349 | +810 | 1.33% | $ 371.339K |
| CHARLES RIVER LABORATORIES INTERNATIONAL INC | CRL US1598641074 | Equity | 1,556 | +111 | 1.26% | $ 352.885K |
| GRAIL INC | GRAL US3847471014 | Equity | 4,456 | +318 | 1.09% | $ 304.211K |
| ANAPTYSBIO INC | ANAB US0327241065 | Equity | 4,290 | +2,249 | 1.04% | $ 289.575K |
| CRISPR THERAPEUTICS AG | CRSP CH0334081137 | Equity | 5,030 | +359 | 0.98% | $ 274.336K |
| REPLIGEN CORP | RGEN US7599161095 | Equity | 2,009 | +143 | 0.98% | $ 274.108K |
| CADENCE DESIGN SYSTEMS INC | CDNS US1273871087 | Equity | 725 | +180 | 0.97% | $ 272.107K |
| BEAM THERAPEUTICS INC | BEAM US07373V1052 | Equity | 7,577 | +541 | 0.93% | $ 260.043K |
| PRAXIS PRECISION MEDICINES INC | PRAX US74006W2070 | Equity | 718 | +51 | 0.86% | $ 240.379K |
| SARTORIUS AG | SRT3 DE0007165631 | Preferred | 905 | +64 | 0.85% | $ 237.564K |
| AXSOME THERAPEUTICS INC | AXSM US05464T1043 | Equity | 936 | +370 | 0.82% | $ 229.105K |
| CAREDX INC | CDNA US14167L1035 | Equity | 8,000 | +571 | 0.82% | $ 228K |
| JAZZ PHARMACEUTICALS PLC | JAZZ IE00B4Q5ZN47 | Equity | 905 | +64 | 0.78% | $ 218.078K |
|
CATALYST PHARMACEUTICALS INC
|
CPRX US14888U1016 | Equity | 6,865 | +490 | 0.77% | $ 215.767K |
| THERMO FISHER SCIENTIFIC INC | TMO US8835561023 | Equity | 421 | +30 | 0.76% | $ 211.073K |
| IQVIA HOLDINGS INC | IQV US46266C1053 | Equity | 1,082 | +77 | 0.75% | $ 209.064K |
| HINGE HEALTH INC | HNGE US4333131039 | Equity | 2,349 | +167 | 0.70% | $ 194.967K |
| ULTRAGENYX PHARMACEUTICAL INC | RARE US90400D1081 | Equity | 5,131 | +366 | 0.61% | $ 171.324K |
| AGILENT TECHNOLOGIES INC | A US00846U1016 | Equity | 1,223 | +87 | 0.58% | $ 162.451K |
| DANAHER CORP | DHR US2358511028 | Equity | 842 | −208 | 0.57% | $ 160.384K |
| QIAGEN NV | QGEN NL0015002SN0 | Equity | 3,419 | +244 | 0.48% | $ 133.683K |
| RHYTHM PHARMACEUTICALS INC | RYTM US76243J1051 | Equity | 1,048 | +74 | 0.42% | $ 116.359K |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT US03969K1088 | Equity | 4,422 | +315 | 0.42% | $ 115.945K |
| SAMSUNG EPIS HOLDINGS CO LTD | 0126Z0 KR70126Z0002 | Equity | 376 | +26 | 0.37% | $ 104.357K |
| KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | KNSA GB00BRXB0C07 | Equity | 1,479 | new +1,479 | 0.34% | $ 94.582K |
| TARSUS PHARMACEUTICALS INC | TARS US87650L1035 | Equity | 1,136 | −351 | 0.26% | $ 71.5K |
| BIO-RAD LABORATORIES INC | BIO US0905722072 | Equity | 243 | +17 | 0.26% | $ 71.347K |
| LIQUIDIA CORP | LQDA US53635D2027 | Equity | 871 | new +871 | 0.25% | $ 69.445K |
| BRISTOL-MYERS SQUIBB COMPANY | BMY US1101221083 | Equity | 1,196 | +85 | 0.25% | $ 68.914K |
| TG THERAPEUTICS INC | TGTX US88322Q1085 | Equity | 1,253 | new +1,253 | 0.25% | $ 68.84K |
| BEONE MEDICINES LTD | ONC US07725L1026 | Equity | 225 | +16 | 0.23% | $ 64.118K |
| NEUROGENE INC | NGNE US64135M1053 | Equity | 1,981 | +141 | 0.22% | $ 62.302K |
| FIRST TRACKS BIOTHERAPEUTICS INC | TRAX US3371851029 | Equity | 2,775 | new +2,775 | 0.20% | $ 55.833K |
| GENEDX HOLDINGS CORP | WGS US81663L2007 | Equity | 575 | −834 | 0.14% | $ 39.474K |
| WAVE LIFE SCIENCES LTD | WVE SG9999014716 | Equity | 4,813 | +343 | 0.10% | $ 27.964K |
| RECURSION PHARMACEUTICALS INC | RXRX US75629V1044 | Equity | 5,507 | −4,886 | 0.07% | $ 20.211K |
|
OMNIAB INC
|
2200963D US68218J2024 | Equity | 240 | 0 | 0.00% | $ 0.00 |
|
OMNIAB INC
|
2200964D US68218J3014 | Equity | 240 | 0 | 0.00% | $ 0.00 |
Trades Mar 31, 2026 to Jun 30, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| GUARDANT HEALTH INC | GH | Bought | 15,718 | 16,927 | +1,209 | $ 181.386K |
| ANAPTYSBIO INC | ANAB | Bought | 2,041 | 4,290 | +2,249 | $ 151.808K |
| TRAVERE THERAPEUTICS INC | TVTX | Bought | 10,129 | 12,753 | +2,624 | $ 149.069K |
| NATERA INC | NTRA | Bought | 7,131 | 7,679 | +548 | $ 148.755K |
| KRYSTAL BIOTECH INC | KRYS | Bought | 4,418 | 4,757 | +339 | $ 125.996K |
| ELI LILLY & COMPANY | LLY | Bought | 593 | 688 | +95 | $ 113.946K |
| MEDPACE HOLDINGS INC | MEDP | Sold | 1,327 | 1,133 | −194 | $ -102.74K |
| KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | KNSA | New | — | 1,479 | +1,479 | $ 94.582K |
| LIGAND PHARMACEUTICALS INC | LGND | Bought | 3,794 | 4,085 | +291 | $ 91.982K |
| AXSOME THERAPEUTICS INC | AXSM | Bought | 566 | 936 | +370 | $ 90.565K |
| ADAPTIVE BIOTECHNOLOGIES CORP | ADPT | Bought | 48,245 | 51,956 | +3,711 | $ 79.601K |
| UNITED THERAPEUTICS CORP | UTHR | Bought | 1,680 | 1,809 | +129 | $ 69.896K |
| BRIDGEBIO PHARMA INC | BBIO | Bought | 12,192 | 13,129 | +937 | $ 69.788K |
| LIQUIDIA CORP | LQDA | New | — | 871 | +871 | $ 69.445K |
| TG THERAPEUTICS INC | TGTX | New | — | 1,253 | +1,253 | $ 68.84K |
| CADENCE DESIGN SYSTEMS INC | CDNS | Bought | 545 | 725 | +180 | $ 67.558K |
| IONIS PHARMACEUTICALS INC | IONS | Bought | 5,957 | 6,739 | +782 | $ 62.005K |
| NEUROCRINE BIOSCIENCES INC | NBIX | Bought | 2,693 | 3,058 | +365 | $ 61.515K |
| VERACYTE INC | VCYT | Bought | 6,788 | 7,819 | +1,031 | $ 60.551K |
| GENEDX HOLDINGS CORP | WGS | Sold | 1,409 | 575 | −834 | $ -57.254K |
| TWIST BIOSCIENCE CORP | TWST | Bought | 7,184 | 7,736 | +552 | $ 56.79K |
| FIRST TRACKS BIOTHERAPEUTICS INC | TRAX | New | — | 2,775 | +2,775 | $ 55.833K |
| VERTEX PHARMACEUTICALS INC | VRTX | Bought | 1,435 | 1,545 | +110 | $ 54.64K |
| ASTRAZENECA PLC | AZN | Bought | 3,695 | 3,979 | +284 | $ 53.852K |
| INSMED INC | INSM | Bought | 5,932 | 6,388 | +456 | $ 48.619K |
| TransMedics Group Inc. | TMDX | Closed | 482 | — | −482 | $ -47.916K |
| CORTEVA INC | CTVA | Bought | 6,904 | 7,435 | +531 | $ 44.97K |
| SAMSUNG BIOLOGICS CO LTD | 207940 | Bought | 652 | 702 | +50 | $ 44.891K |
| DANAHER CORP | DHR | Sold | 1,050 | 842 | −208 | $ -39.62K |
| TEMPUS AI INC | TEM | Bought | 8,726 | 9,397 | +671 | $ 38.871K |
| ALNYLAM PHARMACEUTICALS INC | ALNY | Bought | 1,687 | 1,816 | +129 | $ 38.833K |
| REGENERON PHARMACEUTICALS INC | REGN | Bought | 748 | 805 | +57 | $ 35.542K |
| ARGENX SE | ARGX | Bought | 459 | 494 | +35 | $ 32.469K |
| PTC THERAPEUTICS INC | PTCT | Bought | 4,652 | 5,009 | +357 | $ 29.12K |
| STOKE THERAPEUTICS INC | STOK | Bought | 10,539 | 11,349 | +810 | $ 26.503K |
| CHARLES RIVER LABORATORIES INTERNATIONAL INC | CRL | Bought | 1,445 | 1,556 | +111 | $ 25.174K |
| TARSUS PHARMACEUTICALS INC | TARS | Sold | 1,487 | 1,136 | −351 | $ -22.092K |
| GRAIL INC | GRAL | Bought | 4,138 | 4,456 | +318 | $ 21.71K |
| CRISPR THERAPEUTICS AG | CRSP | Bought | 4,671 | 5,030 | +359 | $ 19.58K |
| REPLIGEN CORP | RGEN | Bought | 1,866 | 2,009 | +143 | $ 19.511K |
| BEAM THERAPEUTICS INC | BEAM | Bought | 7,036 | 7,577 | +541 | $ 18.567K |
| RECURSION PHARMACEUTICALS INC | RXRX | Sold | 10,393 | 5,507 | −4,886 | $ -17.932K |
| BIONTECH SE | BNTX | Sold | 4,340 | 4,156 | −184 | $ -17.121K |
| PRAXIS PRECISION MEDICINES INC | PRAX | Bought | 667 | 718 | +51 | $ 17.074K |
| SARTORIUS AG | SRT3 | Bought | 841 | 905 | +64 | $ 16.8K |
| CAREDX INC | CDNA | Bought | 7,429 | 8,000 | +571 | $ 16.274K |
| JAZZ PHARMACEUTICALS PLC | JAZZ | Bought | 841 | 905 | +64 | $ 15.422K |
|
CATALYST PHARMACEUTICALS INC
|
CPRX | Bought | 6,375 | 6,865 | +490 | $ 15.401K |
| THERMO FISHER SCIENTIFIC INC | TMO | Bought | 391 | 421 | +30 | $ 15.041K |
| IQVIA HOLDINGS INC | IQV | Bought | 1,005 | 1,082 | +77 | $ 14.878K |
| HINGE HEALTH INC | HNGE | Bought | 2,182 | 2,349 | +167 | $ 13.861K |
| ULTRAGENYX PHARMACEUTICAL INC | RARE | Bought | 4,765 | 5,131 | +366 | $ 12.221K |
| AGILENT TECHNOLOGIES INC | A | Bought | 1,136 | 1,223 | +87 | $ 11.556K |
| Caris Life Sciences Inc. | CAI | Closed | 557 | — | −557 | $ -9,959.16 |
| QIAGEN NV | QGEN | Bought | 3,175 | 3,419 | +244 | $ 9,540.40 |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | Bought | 4,107 | 4,422 | +315 | $ 8,259.30 |
| RHYTHM PHARMACEUTICALS INC | RYTM | Bought | 974 | 1,048 | +74 | $ 8,216.22 |
| SAMSUNG EPIS HOLDINGS CO LTD | 0126Z0 | Bought | 350 | 376 | +26 | $ 7,216.16 |
| BIO-RAD LABORATORIES INC | BIO | Bought | 226 | 243 | +17 | $ 4,991.37 |
| BRISTOL-MYERS SQUIBB COMPANY | BMY | Bought | 1,111 | 1,196 | +85 | $ 4,897.70 |
| BEONE MEDICINES LTD | ONC | Bought | 209 | 225 | +16 | $ 4,559.52 |
| NEUROGENE INC | NGNE | Bought | 1,840 | 1,981 | +141 | $ 4,434.45 |
| WAVE LIFE SCIENCES LTD | WVE | Bought | 4,470 | 4,813 | +343 | $ 1,992.83 |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up